Analysis Titer of Epidermal Growth Factor Receptor on Nasopharyngeal Cancer Patients Based on Stadium and Histopathological Profile in Dr. Zainoel Abidin General Hospital Banda Aceh by Kurnia, Benny et al.
International Journal of Nasopharyngeal Carcinoma (IJNPC) Vol. 03, No. 01, March, 2021 | 1-4 
 




Journal homepage: https://talenta.usu.ac.id/IJNPC 
 
 





Analysis Titer of Epidermal Growth Factor Receptor on Nasopharyngeal Cancer Patients 
Based on Stadium and Histopathological Profile in Dr. Zainoel Abidin General Hospital 
Banda Aceh 
Benny Kurnia1, Fera Kamila Kamal1*, Basri Abdul Gani2 
1Otorhinolaryngology Head and Neck Surgery Department, Faculty of Medicine, Syiah Kuala University, Banda Aceh, Indonesia  
2Faculty of Dentistry, Syiah Kuala University, Banda Aceh, Indonesia 
Abstract Article Info 
Introduction: Nasopharyngeal carcinoma ranks first in incidence at the head and the neck departement. 
Epidermal Growth Factor Receptor (EGFR) is a transmembrane tyrosine kinase receptor from the ErbB family. 
Excess EGFR titer is an indication of a malignant transformation and cell differentiation that can ultimately 
determine the effectiveness of using anti EGFR drugs nasopharyngeal carcinoma patients. 
Objective: To determine the EGFR titer of nasopharyngeal cancer tissue based on the stage and histopathological 
profile in Dr. Zainoel Abidin Banda Aceh. 
Methods: Patients with suspected nasopharyngeal carcinoma were subjected to a nasopharyngeal biopsy 
examination, some samples were sent to the Anatomical Pathology Laboratory of the General Hospital Dr. 
Zainoel Abidin Banda Aceh for histopathological examination and some were sent to the Research Laboratory 
of the Faculty of Dentistry, Syiah Kuala University for examination of EGFR titers. This study was conducted 
from January 2020 to October 2020. 
Results: There were 17 samples of nasopharyngeal carcinoma. Based on the results of the Paired T test analysis, 
it can be seen that there is a difference in the quantity of EGFR titers of each study subject with the variable 
stage and histopathological profile. Specifically, the Paired T test analysis between EGFR titers and Stadium 
(P<0.05; 0.00); and analysis of EGFR titer with histopathological profile (P<0.05; 0.00). In general, the 
Friedmann test analysis showed that there were significant differences in the incidence of nasopharyngeal 
carcinoma in patients with regard to age, histopathological profile and stage (P<0.05). 
Conclusion: EGFR titer quantity has a positive relationship with nasopharyngeal carcinoma stage and there is 
no relationship between EGFR titer and histopathological profile of nasopharyngeal carcinoma 
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Nasopharyngeal carcinoma is a malignant tumor originating from 
the nasopharyngeal epithelium with the most common from 
Rosenmuller fossa [1]. Nasopharyngeal carcinoma is more common in 
Mongoloid races. The incidence rate is relatively high in South China 
at 20 to 40 per 100,000 per year [2]. The incidence of nasopharyngeal 
carcinoma in Indonesia reaches 4.7 per 100,000 population per year [3]. 
The World Health Organization (WHO) developed classification of 
nasopharyngeal carcinoma into keratinizing squamous cell carcinoma 
(Type 1), nonkeratinizing squamous cell carcinoma (Type 2) and 
undifferentiated squamous cell carcinoma (Type 3) [4]. Epidermal 
Growth Factor Receptor (EGFR) is a glycoprotein transmembrane made 
by "protooncogen c-erb-B2". Epidermal Growth Factor Receptors are 
increased in some carcinomas. This protein is expressed in small 
amounts in human tissue, but activation of the protooncogen "c-erb-B2" 
causes overexpression in many types of cancer in humans [1]. EGFR 
activation signals an increase in cell proliferation, angiogenesis and 
decrease in the apoptosis process. Increased expression of EGFR is also 
associated with the severity of the tumor stage such as tumor size, 
lymph node involvement and distant metastases, thus associated with 
prognosis [5]. In the last two decades, EGFR is the first receptor as a 
target therapy in cancer therapy with several forms of anti-EGFR drugs 
that are can be used clinically [6]. This study was conducted to 
determine the expression of EGFR protein titer in patients with 
nasopharyngeal carcinoma based on the stage and histopathological 
profile. 
2. MATERIALS AND METHODS 
This research is an observational analytic study based on molecular 
biology. The sampling site was carried out in the ENT-KL clinic at Dr. 
Zainoel Abidin General Hospital Banda Aceh. The histopathological 
examination was carried out at the Anatomical Pathology Laboratory of the 
Dr. Zainoel Abidin General Hospital Banda Aceh. The EGFR examination 
was carried out at the Research Laboratory of the Faculty of Dentistry, Syiah 
Kuala University. This research was conducted in January 2020 to October 
2020. The samples are all patients diagnosed with new cases of 
nasopharyngeal carcinoma based on the results of histopathological 
examination were in accordance with WHO criteria and met the inclusion 
criteria. Based on the sample formula for estimating one proportion, a total 
sample size of 17 samples was obtained for examination of the EGFR titer 
analysis. Inclusion criteria are all patients who went to the ENT-KL clinic 
in Dr. Zainoel Abidin General Hospital Banda Aceh and diagnosed with new 
cases of nasopharyngeal carcinoma. Age range 18 to 70 years. 
Nasopharyngeal carcinoma patients who are not diagnosed with other 
malignancies. Statistical analysis using IBM SPSS software, EGFR titer 
data associated with staging and histopathological profiles were analyzed 
by Paired sample t-test, while the relationship was analyzed by Paired t-test 
correlation and Spearmann Rho. Data on the significance relationship 
between EGFR and all analysis variables were tested by the Friedman test 
with a limit of significance P<0.05 and a limit of correlation strength (r=1).                                      
 








Baseline data recorded in this study included age, histopathological 
profile, and stage. 
Table 1. The results obtained from the age range 
 
Age (year) Amount % 
30-40 4 23,5 










Total 17 100,00 
 
 From the table above, the results obtained from the age range of 30-40 
years are 4 (23.5%) patients, 4 (23.5%) patients, 41-60 years (4 (29.5%)) 
patients, and 61-70 years as many as 4 (23.5%) patients. In this study, the 
youngest age was 30 years and the oldest was 68 years old. The mean age 
was 49 years. Most sufferers are found in the age range 51-60 as many as 5 
sufferers. 
Table 2. The results obtained from the gender 
 
Gender Amount % 
Male 9 52 
Female 8 48 
Total 17 100 
 
From the table above, it is found that 9 (52%) men (52%) sufferers and 8 
(48%) women sufferers. From the table above, there are more male 
sufferers than female sufferers 
Table 3. The results of the histopathological profile 
Histopathological profile Amount % 
WHO Type1 1 6 
WHO Type 2 13 76 
WHO Type 3 3 18 
Total 17 100 
From the table above, the results of the histopathological profile of type 
1 WHO were 1 (6%) patients, type 2 WHO was 13 (76%) patients, and type 
3 WHO was 3 (18%) patients 
Table 4. The results of the stage 
Stage Amount % 
0 0 0 
I 0 0 
















Total 17 100 
From the table above, it is found that there are no patients with stages 0 
to II. Patients with stage III were 3 (18%) patients, Stage IVa were 13 (76%) 
patients and Stage IVb were 1 (6%) patients.  
 
Graphic 1.  EGFR titer quantification of nasopharyngeal carcinoma 
 
Graphic 1 shows that the EGFR titer quantification is seen to be the 
highest (0.498 ppm) in sample number 8, and the lowest seen in sample 
number 4 (0.025ppm). 































2 Female 64       2 IVa 0.278 
3 Male 67 2 III 0.025 
4 Female 68 2 III 0.021 
5 Female 46 2 III 0.028 
6 Male 55 2 IVa 0.264 
7 Female 53 2 IVa 0.148 
8 Female 34 1 IVa 0.498 
9 Male 53 2 IVa 0.375 
10 Male 43 2 IVa 0.105 
11 Female 38 2 IVa 0.117 
12 Male 41 3 IVa 0.028 
13 Male 56 3 IVa 0.105 
14 Male 54 2 IVa 0.166 
15 Female 38 2 IVa 0.241 
16 Male 30 2 IVa 0.348 
17 Male 45 2 IVa 0.479 
 
Table 5 shows that the EGFR titers based on stage and histopathological 
profile. The highest EGFR titer was seen in stage IVa and the 
histopathological profile of keratinizing squamose cell carcinoma.  
Based on the results of the Paired T test analysis, it shows that there are 
differences in the quantity of EGFR titers of each study subject with variables of 
age, histopathological profile and cancer stage. Specifically, the Paired T test 
analysis between EGFR protein titer and age (P<0.05; 0.00); EGFR titer analysis 
with staging (P<0.05; 0.00); and analysis of EGFR titer with histopathological 
profile (P<0.05; 0.00). In general, the Friedmann test analysis showed that there 
were significant differences in nasopharyngeal carcinoma with respect to age, 
histopathological profile and stage (P<0.05). Based on the correlation analysis 
Paired T test shows that the EGFR titer has a significant relationship with the 
stage, meaning that the higher the stage, the higher the EGFR titer (positive 
correlation), while the relation between EGFR titers and age has a negative 
correlation. The expression of EGFR protein titer had no relationship with the 
histopathological profile. In addition, based on the non-parametric correlation 
test (Spearman'rho), it showed that the EGFR protein titer was a significant 
determinant (P<0.05: 0.037). 








The general objective of this study was to evaluate the EGFR titer of 
nasopharyngeal carcinoma tissue based on staging and histopathological 
profile. The data obtained specifically analyzed the relationship between 
EGFR titer expression with the stage of nasopharyngeal carcinoma and the 
histopathological profile of nasopharyngeal carcinoma. The selection of 
EGFR protein titer in this study is related to the nature of the protein which 
acts as a receptor that responds to the growth of cancer cells. EGFR is 
usually overexpressed in nasopharyngeal carcinoma and is associated with 
its pathogenesis [7].  
Increased EGFR titer is very common in nasopharyngeal carcinoma. It 
is estimated to be 85%. In addition, overexpression of EGFR titers in 
nasopharyngeal carcinoma is associated with tumor metastasis, progression, 
and poor survival in patients with nasopharyngeal carcinoma [8]. Increased 
expression of EGFR is also associated with the severity of the tumor stage 
such as tumor size, lymph node involvement and distant metastases, so it is 
associated with prognosis [9]. Prabowo et al compared the expression of 
stage III and IV EGFR, found that all stage III nasopharyngeal carcinomas 
showed negative EGFR while at stage IV all were obtained with positive 
EGFR [10]. Sukri Rahman et al also had excess EGFR results in advanced 
nasopharyngeal carcinoma.[11]. 
Prabowo et al also mentioned that EGFR is highly expressed in 
advanced nasopharyngeal carcinoma [12]. These results are in line with this 
study, it was found that the expression of high EGFR titers occurred at stages 
IVa and IVb. The meaning the development of this tumor is strongly 
influenced by the EGFR titer. It shows a statistically significant relationship. 
So it can be assumed that EGFR plays an important role in the development 
and development of nasopharyngeal carcinoma because EGFR is one of the 
tyrosine kinase receptors that plays the most role through the binding 
mechanism between EGF and TGF-α ligands with the EGFR extracellular 
domain, thereby activating receptors and signaling proteins that trigger 
activation. or modulation of various cellular processes [13]. 
In general, the data of this study indicate the age is under 55 years have 
a tendency to express EGFR titer higher than those over 55 years of age. 
This data is in line with Bray's research report which states that interesting 
epidemiological observations at the initial peak in the age curve of incidence 
observed in geographically different populations indicate different causal 
entities and the likelihood of fatigue of susceptible individuals from the 
population at a given age. Results of systematic evaluation of the age profile 
of the incidence of nasopharyngeal carcinoma worldwide on population 
partitioning by risk level using data from 23 high-quality population-based 
cancer registries found a consistent pattern of bimodality. Continued 
increase in risk of nasopharyngeal carcinoma at age until the first peak in 
late adolescence / early adulthood (ages 15-24 years) [14]. Age at diagnosis 
has been found to be a prognostic factor in outcome in various cancers. 
However, the effect of age at diagnosis on the development of 
nasopharyngeal carcinoma has not been explored.  
Xie's study data reported that correlation analysis showed that age >61 
years was significantly correlated with tumor progression and therapeutic 
measures in cohort testing and validation (P<0.05). Furthermore he 
observed that older age (>61 years) was a strong predictor (P<0.05) of 
cancer-specific survival [15]. This study's data correlated with age-specific 
nasopharyngeal cancer incidence, but when associated with titer expression. 
EGFR, precisely at the age above 55 years of age had a decrease in EGFR 
expression (negative relationship), but had a significance (P<0.05) for the 
development of nasopharyngeal cancer based on the EGFR titer which 
decreased with age. These two findings provide mutual insight into the level 
of influence of EGFR titer on the development of nasopharyngeal carcinoma 
in the elderly. From these findings, it can be seen that in the development of 
nasopharyngeal carcinoma over 55 years of age the EGFR protein is no 
longer involved in a dominant manner. protooncogen protein, protein G, and 
other protein kinases are reported to have balanced stability in the 
pathogenesis of cancer in the elderly [16]. Based on the results of this study, 
the EGFR titer has a low sensitivity in old age, so that the possibility of 
eliminating cancer in the elderly with the help of other treatments besides 
anti-egfr is preferred [17]. 
Based on the data obtained from this study, it can be seen that there is a 
difference in the EGFR titer between the early stage and the advanced stage 
of nasopharingeal carcinoma. In stage III, it is only seen that sometimes the 
average EGFR titer is 0.025 ppm, while in the advanced stages (IVa and 
IVb) it looks much higher. The development of EGFR titers at this advanced 
stage is associated with metastasis of nasopharyngeal carcinoma as well as 
suppression of the immune system and inhibition of apoptosis of cancer 
cells. The increase in the EGFR titer which increases with increasing stage 
shows a significant incidence of cancer cell defense [18]. Chua reported that 
the expression of EGFR titers was common in cases nasopharyngeal 
carcinoma at an advanced stage. Correlative analysis shows that EGFR level 
is a strong independent prognostic factor that determines disease-specific 
survival in stage III-IV nasopharyngeal carcinoma. The findings of Chua et 
al. Suggest that the expression status of EGFR titers can identify a subgroup 
of patients with advanced disease, so that anti-EGFR targeted therapy and 
treatment strategies can be determined. Furthermore, Utomo confirmed that 
the expression EGFR is related to development of the stage of 
nasopharyngeal cancer [19]. 
Alni et al. Stated that the distribution of nasopharyngeal malignancy 
according to histopathological type according to the classification based on 
WHO criteria found that the type of undifferentiated carcinoma (WHO type 
III) had the highest number, namely 136 (68.3%) cases. Then followed by 
the non-keratinizing type squamous cell carcinoma (WHO type II) as many 
as 60 (30.2%) cases and type keratinizing squamous cell carcinoma (WHO 
type I) had the lowest rate, namely 3 (1.5%) cases in hospitals in Pekanbaru 
City [20]. In this study, it was found that the most type was non keratinizing 
squamous cell carcinoma (WHO type II). The similarity is that the 
distribution of nasopharyngeal malignancy according to histopathological 
type is in accordance with the classification based on WHO criteria. In this 
study, it was found that WHO type 1 had the lowest number, which was only 
1 (6%) sample from all 17 samples studied. Sukri Rahman et al in their 
research stated that there was no difference in EGFR expression between 
non keratinizing squamous cell carcinoma (WHO type II) and type 
undifferentiated carcinoma (WHO type III) [11]. Nyoman in his research 
also concluded that EGFR was expressed differently in various head and 
neck cancers, but there was no relationship between EGFR expression with 
clinicopathological characteristics and tumor location.[21] In line with 
previous studies in this study, a histopathological assessment also showed 
that the expression of EGFR titer had no significant relationship with 
histopathological profile, meaning that this titer expression was not 
determined by profile. histopathological. 
The findings of this study and comparison with the results of previous 
studies can be used as a reference for the treatment of nasopharyngeal cancer 
through the EGFR work system approach. Another basis for consideration 
is that an increased EGFR titer is correlated with a decrease in patient 
survival [22]. Recent data have proposed EGFR as a new target for cancer 
therapy In addition, EGFR is the first receptor as a target therapy in cancer 
therapy with various anti-EGFRs through the principle of prevention and 
anti-cancer mechanisms through molecular target therapy and 
immunotherapy [23].  
5. CONCLUSION 
All subjects of nasopharyngeal carcinoma had different expression of 
egfr titers based on stage and histopathological profile. EGFR titer quantity 
has a positive relationship with nasopharyngeal carcinoma stage and there 
is no relationship between EGFR titer and histopathological profile of 
nasopharyngeal carcinoma. Further studies with more samples are needed 
to see the correlation effect. Stage and histopathological profile with 
incidence of nasopharyngeal cancer.  
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